Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M. Chougnet CN, et al. Among authors: niccoli p. Thyroid. 2015 Apr;25(4):386-91. doi: 10.1089/thy.2014.0361. Epub 2015 Feb 18. Thyroid. 2015. PMID: 25627619
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Borson-Chazot F, Dantony E, Illouz F, Lopez J, Niccoli P, Wassermann J, Do Cao C, Leboulleux S, Klein M, Tabarin A, Eberle MC, Benisvy D, de la Fouchardière C, Bournaud C, Lasolle H, Delahaye A, Rabilloud M, Lapras V, Decaussin-Petrucci M, Schlumberger M. Borson-Chazot F, et al. Among authors: niccoli p. Thyroid. 2018 Sep;28(9):1174-1179. doi: 10.1089/thy.2017.0663. Thyroid. 2018. PMID: 30105951 Clinical Trial.
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR.
de la Fouchardière C, Godbert Y, Dalban C, Illouz F, Wassermann J, Do Cao C, Bardet S, Zerdoud S, Chougnet CN, Zalzali M, Benisvy D, Niccoli P, Digue L, Lamartina L, Schwartz P, Borson Chazot F, Gautier J, Pérol D, Leboulleux S; PAZOTHYR investigators. de la Fouchardière C, et al. Among authors: niccoli p. Eur J Cancer. 2021 Nov;157:153-164. doi: 10.1016/j.ejca.2021.07.029. Epub 2021 Sep 9. Eur J Cancer. 2021. PMID: 34509954 Free article. Clinical Trial.
Is thyroid cancer recurrence risk increased after transplantation?
Tisset H, Kamar N, Faugeron I, Roy P, Pouteil-Noble C, Klein M, Mourad G, Drui D, Do Cao C, Leenhardt L, Allix I, Bonichon F, Morelon E, Leboulleux S, Kelly A, Niccoli P, Toubert ME, Frimat L, Vantyghem MC, Bournaud C, Schlumberger M, Borson-Chazot F; TUTHYREF network. Tisset H, et al. Among authors: niccoli p. J Clin Endocrinol Metab. 2013 Oct;98(10):3981-8. doi: 10.1210/jc.2013-1357. Epub 2013 Jul 24. J Clin Endocrinol Metab. 2013. PMID: 23884779
One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.
Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, de la Fouchardiere C, Libé R, Do Cao C, Niccoli P, Tabarin A, Raingeard I, Chougnet C, Giraud S, Gimenez-Roqueplo AP, Young J, Borson-Chazot F, Bertherat J, Wemeau JL, Bertagna X, Plouin PF, Schlumberger M, Baudin E; French group of Endocrine and Adrenal tumors (Groupe des Tumeurs Endocrines-REseau NAtional des Tumeurs ENdocrines and COrtico-MEdullo Tumeurs Endocrines networks). Hescot S, et al. Among authors: niccoli p. J Clin Endocrinol Metab. 2013 Oct;98(10):4006-12. doi: 10.1210/jc.2013-1907. Epub 2013 Jul 24. J Clin Endocrinol Metab. 2013. PMID: 23884775
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study.
Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L, de la Fouchardière C, Valdes N, Riccardi F, Do Cao C, Bertherat J, Goichot B, Beuschlein F, Drui D, Canu L, Niccoli P, Laboureau S, Tabarin A, Leboulleux S, Calsina B, Libé R, Faggiano A, Schlumberger M, Borson-Chazot F, Mannelli M, Gimenez-Roqueplo AP, Caron P, Timmers HJLM, Fassnacht M, Robledo M, Borget I, Baudin E; European Network for the Study of Adrenal Tumors (ENS@T). Hescot S, et al. Among authors: niccoli p. J Clin Endocrinol Metab. 2019 Jun 1;104(6):2367-2374. doi: 10.1210/jc.2018-01968. J Clin Endocrinol Metab. 2019. PMID: 30715419 Free article.
Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines.
Rohmer V, Vidal-Trecan G, Bourdelot A, Niccoli P, Murat A, Wemeau JL, Borson-Chazot F, Schvartz C, Tabarin A, Chabre O, Chabrier G, Caron P, Rodien P, Schlumberger M, Baudin E; Groupe Français des Tumeurs Endocrines. Rohmer V, et al. Among authors: niccoli p. J Clin Endocrinol Metab. 2011 Mar;96(3):E509-18. doi: 10.1210/jc.2010-1234. Epub 2010 Dec 29. J Clin Endocrinol Metab. 2011. PMID: 21190982
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E. Faivre S, et al. Among authors: niccoli p. Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561. Ann Oncol. 2017. PMID: 27836885 Free article. Clinical Trial.
80 results